Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.

[1] It selectively binds to carcinoembryonic cell adhesion molecule 5.

[2] Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.